Examkin

Question

Difficulty: HardGeneral Internal Medicine

Match each patient scheduled for an elective surgical or endoscopic procedure with the most appropriate perioperative medication management strategy.

  • A 68-year-old man with a mechanical aortic valve (no history of atrial fibrillation or stroke) on warfarin, scheduled for an elective laparoscopic cholecystectomy.Discontinue the vitamin K antagonist 5 days prior to surgery without initiating bridging anticoagulation.
  • A 54-year-old woman with nonvalvular atrial fibrillation (CHA2DS2-VASc score = 1) on apixaban, scheduled for a screening colonoscopy with planned polypectomy.Discontinue the direct oral anticoagulant 48-72 hours prior to the procedure; bridging anticoagulation is not indicated.
  • A 62-year-old man with severe rheumatoid arthritis on methotrexate and infliximab, scheduled for an elective total knee arthroplasty.Withhold the biologic agent for one full dosing cycle prior to surgery; continue the antimetabolite medication uninterrupted.
  • A 58-year-old woman with type 2 diabetes on empagliflozin and daily glargine insulin, scheduled for an elective open hemicolectomy.Discontinue the sodium-glucose cotransporter-2 inhibitor 3-4 days preoperatively; administer a reduced dose of the basal insulin on the morning of surgery.

Answer

The correct matches align each patient's specific preoperative risk profile (thromboembolic, bleeding, infectious, and metabolic) with the appropriate medication modification: low-risk mechanical valves do not require bridging; DOACs are held without bridging; biologic DMARDs are held while methotrexate is continued; and SGLT2 inhibitors are held 3-4 days preoperatively while basal insulin is reduced.
Each management strategy is supported by current clinical guidelines aimed at minimizing both surgical complications (bleeding, infection) and exacerbations of the patient's underlying chronic conditions.

Step-by-Step Solution

1
Evaluate the thromboembolic risk for the patient with a mechanical aortic valve to determine the need for bridging anticoagulation.
The patient is determined to be at low thromboembolic risk.
Bridging anticoagulation is not indicated for low-risk patients, so warfarin is simply stopped 5 days prior to surgery.
2
Assess the pharmacokinetics and bridging requirements for apixaban in a patient with atrial fibrillation.
Apixaban is held 48-72 hours prior to the procedure.
DOACs have rapid offset and short half-lives; bridging with heparin increases bleeding risk without any proven benefit and is contraindicated.
3
Differentiate the perioperative management of biologic versus non-biologic DMARDs.
Infliximab is withheld, while methotrexate is continued.
Biologics significantly increase postoperative infection risk and must be held. Conversely, holding methotrexate increases the risk of debilitating RA flares without significantly altering infection risk.
4
Formulate a fasting management plan for a patient's diabetes medications.
Empagliflozin is held 3-4 days prior, and glargine insulin is administered at a reduced dose.
SGLT2 inhibitors can cause perioperative euglycemic DKA. Basal insulin prevents DKA and severe hyperglycemia but must be reduced to avoid fasting hypoglycemia on the morning of surgery.

Key Concept

Perioperative medication management requires balancing the risks of disease exacerbation (e.g., thrombosis, RA flare, DKA) against surgical complications (e.g., bleeding, infection, hypoglycemia).
Estimated Time:2m 0s
Rate this question

Topics

General Internal Medicine

More questions from this topic